Cancer Letters
Volume 222, Issue 1 , Pages 75-81 , 10 May 2005

HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast

  • Paola Parrella

      Affiliations

    • Laboratory of Gene Therapy and Oncology, IRCCS, ‘Casa Sollievo della Sofferenza’, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0882 416262; fax: +39 0882 416260.
    • ,
  • Marina Scintu

      Affiliations

    • Laboratory of Gene Therapy and Oncology, IRCCS, ‘Casa Sollievo della Sofferenza’, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy
    • ,
  • Maria Prencipe

      Affiliations

    • Laboratory of Gene Therapy and Oncology, IRCCS, ‘Casa Sollievo della Sofferenza’, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy
    • ,
  • Maria Luana Poeta

      Affiliations

    • CIR Section of Molecular Medicine and Biotechnology, ‘Campus BioMedico University’, Rome, Italy
    • ,
  • Antonietta Pia Gallo

      Affiliations

    • Laboratory of Gene Therapy and Oncology, IRCCS, ‘Casa Sollievo della Sofferenza’, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy
    • ,
  • Carla Rabitti

      Affiliations

    • Department of Pathology, ‘Campus BioMedico University’, Rome, Italy
    • ,
  • Monica Rinaldi

      Affiliations

    • Neurobiology and Molecular Medicine Institute, CNR, Rome, Italy
    • ,
  • Stefania Tommasi

      Affiliations

    • Clinical Experimental Oncology Laboratory, and Department ‘Donna’, National Cancer Institute, Bari, Italy
    • ,
  • Angelo Paradiso

      Affiliations

    • Clinical Experimental Oncology Laboratory, and Department ‘Donna’, National Cancer Institute, Bari, Italy
    • ,
  • Francesco Schittulli

      Affiliations

    • Clinical Experimental Oncology Laboratory, and Department ‘Donna’, National Cancer Institute, Bari, Italy
    • ,
  • Vanna Maria Valori

      Affiliations

    • Department of Onco-Hematology IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo (FG), Italy
    • ,
  • Salvatore Toma

      Affiliations

    • Department of Onco-Hematology IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo (FG), Italy
    • ,
  • Vittorio Altomare

      Affiliations

    • Breast Unit, Department of Surgery, ‘Campus BioMedico University’, Rome, Italy
    • ,
  • Vito Michele Fazio

      Affiliations

    • Laboratory of Gene Therapy and Oncology, IRCCS, ‘Casa Sollievo della Sofferenza’, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy
    • CIR Section of Molecular Medicine and Biotechnology, ‘Campus BioMedico University’, Rome, Italy

Received 6 July 2004 ,Revised 25 August 2004 ,Accepted 27 August 2004.

References 

  1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  2. Knudson AG. Cancer genetics. Am. J. Med. Gen. 2002;111:96–102
  3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003;349:2042–2054
  4. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229
  5. Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, et al. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res. 1994;54:4200–4206
  6. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am. J. Pathol. 1998;152:1591–1598
  7. Stack M, Jones D, White G, Liscia DS, Venesio T, Casey G, et al. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum. Mol. Genet. 1995;4:2047–2055
  8. Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, et al. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res. 1998;58:1004–1012
  9. Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W, et al. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J. Pathol. 2001;194:318–326
  10. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1995;1:570–577
  11. Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D. The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol. Cell. Biol. 2002;22:4890–4901
  12. Guerardel C, Deltour S, Pinte S, Monte D, Begue A, Godwin AK, et al. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J. Biol. Chem. 2001;276:3078–3089
  13. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 2002;8:3324–3331
  14. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res. 2002;62:3794–3797
  15. Fujii H, Biel MA, Zhou W, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 1998;16:2159–2164
  16. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet. 2003;33:197–202
  17. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 2001;61:7623–7626
  18. Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL. Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1–p25.2. Cancer Res. 2003;63:8507–8510
  19. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996;24:5064–5066
  20. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 2001;7:1982–1986
  21. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006
  22. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, et al. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res. 2002;62:1939–1943
  23. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 1996;56:3655–3658
  24. Simon R, Eltze E, Schafer KL, Burger H, Semjonow A, Hertle L, et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 2001;61:355–362
  25. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001;61:3410–3418
  26. Ha PK, Pilkington TA, Westra WH, Sciubba J, Sidransky D, Califano JA. Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. Int. J. Cancer. 2002;102:615–617
  27. Parrella P, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, et al Non-random distribution of aberrant promoter methylation of known tumor suppressor genes in sporadic breast cancer. Clin. Cancer Res. 2004;10:5349–5354
  28. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60:4366–4371
  29. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl Acad. Sci. USA. 1998;95:8698–8702
  30. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 2004;36:497–501
  31. Tokumaru Y, Nomoto S, Jeronimo C, Henrique R, Harden S, Trink B, et al. Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene. 2003;22:6954–6958

PII: S0304-3835(04)00678-0

doi: 10.1016/j.canlet.2004.08.026

Cancer Letters
Volume 222, Issue 1 , Pages 75-81 , 10 May 2005

Article Tools

* Image Usage & Resolution